Vaborbactam
Vabomere, Vaborem (vaborbactam) is a small molecule pharmaceutical. Vaborbactam was first approved as Vabomere on 2017-08-29. It is used to treat bacterial infections in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vabomere | New Drug Application | 2025-03-25 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX | |||
| 2027-08-29 | GAIN | ||
| 2022-08-29 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J2186 | Injection, meropenem and vaborbactam, 10mg/10mg (20mg) |
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 4 | — | — | 1 | — | 5 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 2 | 1 | — | 3 |
| Multiple drug resistance | D018432 | — | — | — | — | — | 1 | 1 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 2 | — | — | 3 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | 2 | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | 2 | 3 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 2 | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 2 | — | — | 2 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | 1 | 2 |
| Iatrogenic disease | D007049 | — | — | — | — | 1 | — | — | 1 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | 1 | — | — | 1 |
| Intraabdominal infections | D059413 | — | — | — | — | 1 | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gram-negative bacterial infections | D016905 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | — | 1 | 1 |
| Cross infection | D003428 | — | — | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vaborbactam |
| INN | vaborbactam |
| Description | Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.
|
| Classification | Small molecule |
| Drug class | beta-lactamase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1 |
Identifiers
| PDB | — |
| CAS-ID | 1360457-46-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3317857 |
| ChEBI ID | — |
| PubChem CID | 56649692 |
| DrugBank | DB12107 |
| UNII ID | 1C75676F8V (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,854 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
87 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use